Brain energy crisis in Alzheimer's and Parkinson's disease: Nanotechnology as a therapeutic strategy.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic concepts with no primary data
PubMed 42552042 · doi:10.1016/bs.irn.2026.05.016
What was done
This narrative review synthesizes current concepts regarding the failure of brain energy metabolism and mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. It outlines the rationale and delivery mechanisms of various nanotechnology-based platforms—such as polymeric nanoparticles, lipid-based carriers, intranasal nanoformulations, biomimetic vesicles, and catalytic nanozymes—designed to deliver metabolic modulators across the blood-brain barrier.
What was found
The abstract reports no empirical numbers or quantitative findings. It describes the cascade of early glucose hypometabolism, ATP decline, reactive oxygen species accumulation, and neuroinflammation in neurodegenerative disease, and outlines the theoretical capabilities of nanocarriers to improve drug bioavailability, stability, and mitochondrial targeting compared to conventional therapies.
Why it matters
It highlights a conceptual shift toward addressing upstream bioenergetic and mitochondrial failure in neurodegenerative disorders using targeted nanomedicine rather than focusing solely on symptomatic relief or conventional systemic antioxidant administration.
Limits
This publication is a conceptual narrative review without original empirical, preclinical, or human clinical trial data. The abstract provides no quantitative effect sizes, systematic search methodology, or specific safety and pharmacokinetic data, and notes that clinical translation and scalability remain substantial hurdles.
Cited by
- supports Bioenergetic defects in the brain during Alzheimer's disease pathogenesis can predate the onset of clinical cognitive symptoms by 20 to 30 years.